AI medical device for NHS skin cancer screening and triage
Skin Analytics operates a Class III CE-marked AI medical device (DERM) deployed across 25 NHS organizations for skin cancer detection and pathway management. The tech stack is mobile-first (React Native, iOS, Android) with AWS backend infrastructure, and hiring skews toward engineering and clinical roles — reflecting dual complexity: a regulated medical product requiring both software maturity (CI/CD, monitoring, infrastructure) and clinical governance. Active projects center on mobile architecture, regulatory compliance frameworks, and primary care integration, while pain points cluster around international scaling and deployment reliability.
Skin Analytics builds DERM, an AI-powered skin cancer detection system integrated into NHS dermatology workflows. The product screens lesions, triages patients, and helps NHS organizations discharge benign cases earlier, reducing outpatient backlogs and preserving specialist capacity for confirmed cancers. DERM is recommended by NICE and has been deployed across 25 primary and secondary care organizations since 2020, processing over 170,000 NHS patient assessments and identifying more than 15,500 cancers. The company also operates Bupa and Vitality's remote skin assessment service. Based in London with 51–200 employees, Skin Analytics operates under medical device regulation across the UK and expanding markets.
React Native, React, Node.js, TypeScript for mobile and frontend; MySQL, Elasticsearch for data; AWS (SNS, SQS, RDS) for cloud infrastructure; Docker, Terraform for deployment; Bitbucket, GitHub, Jira for version control and CI/CD.
Yes. 4 of 10 active roles are engineering positions (manager, mid, and senior levels). Hiring is currently limited to the United Kingdom.
London, United Kingdom. Founded in 2012, the company remains privately held with 51–200 employees.
Other companies in the same industry, closest in size